Search
Displaying 621–630 of 1079 results
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Researchers Identify Regions in the Retina to Target Therapies for Certain RP Patients
Research NewsUniversity of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
-
In the Press
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing vision loss
-
Accessibility
Zoom is a cloud-based video communications app that allows you to set up virtual video and audio conferencing, webinars, live chats, screen-sharing, and other collaborative capabilities.
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
Research NewsThe company is also expanding its Phase ½ trial for the emerging treatment
-
Foundation News
Accepting grant applications for advancing retinal degeneration treatments toward human studies
-
Bronze Partner - Ora Clinical
-
Bronze Partner - MeiraGTx
-
Research News
A Phase 3 trial for the treatment is planned
